z-logo
Premium
Pharmacological characterization of FE 201874, the first selective high affinity rat V 1A vasopressin receptor agonist
Author(s) -
Marir Rafik,
Virsolvy Anne,
Wisniewski Kazimierz,
Mion Julie,
Haddou Dominique,
Galibert Evelyne,
Meraihi Zahia,
Desarménien Michel G,
Guillon Gilles
Publication year - 2013
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.12249
Subject(s) - agonist , vasopressin , chemistry , receptor , vasopressin receptor , biochemistry , endocrinology , antagonist , biology
Background and Purpose Distinct vasopressin receptors are involved in different physiological and behavioural functions. Presently, no selective agonist is available to specifically elucidate the functional roles of the V 1A receptor in the rat, one of the most widely used animal models. FE 201874 is a new derivative of the human selective V 1A receptor agonist F180 . In this study, we performed a multi‐approach pharmacological and functional characterization of FE 201874 to determine whether it is selective for V 1A receptors. Experimental Approach We modified an available human selective V 1A receptor agonist ( F180 ) and determined its pharmacological properties in cell lines expressing vasopressin/oxytocin receptors (affinity and coupling to second messenger cascades), in an ex vivo model (aorta ring contraction) and in vivo in rats (proliferation of adrenal cortex glomerulosa cells and lactation). Key Results FE 201874 exhibited nanomolar affinity for the rat V 1A receptor; it was highly selective towards the rat V 1B and V 2 vasopressin receptors and behaved as a full V 1A agonist in all the pharmacological tests performed. FE 201874 bound to the oxytocin receptor, but with moderate affinity, and behaved as an oxytocin antagonist in vitro, but not in vivo . Conclusions and Implications On functional grounds, all the data demonstrate that FE 201874 is the first selective agonist of the rat V 1A receptor isoform available. Hence, FE 201874 may have potential as a treatment for the vasodilator‐induced hypotension occurring in conditions such as septic shock and could be the most suitable compound for discriminating between the behavioural effects of arginine vasopressin and oxytocin.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here